Lineage Cell Therapeutics (LCTX) Invested Capital (2014 - 2023)
Lineage Cell Therapeutics (LCTX) posted quarterly Invested Capital of $152000.0 for Q3 2023, up 270.73% year-over-year from $41000.0 in Q3 2022, and down 8.98% quarter-over-quarter from $167000.0 in Q2 2023.
Lineage Cell Therapeutics (LCTX) Invested Capital (2014 - 2023) Analysis & Trends
Lineage Cell Therapeutics' Invested Capital history runs 7 years deep, the most recent figure standing at $152000.0 for Q3 2023.
- In Q3 2023, Invested Capital rose 270.73% year-over-year to $152000.0; the TTM figure through Jun 2024 stood at $152000.0 (down 69.9% YoY), while the FY2022 annual figure was $113000.0, up 213.89% from the prior year.
- Invested Capital for Q3 2023 stood at $152000.0, down from $167000.0 in the prior quarter.
- The five-year high for Invested Capital was $184000.0 in Q1 2023, with the low at $29000.0 in Q3 2021.
- The 5-year median for Invested Capital is $75000.0 (2020), against an average of $85500.0.
- The sharpest annual moves came in 2021 and 2023: Invested Capital plunged 64.52% in 2021, then jumped 270.73% in 2023.
- Lineage Cell Therapeutics' Invested Capital stood at $110000.0 in 2019, then tumbled by 61.82% to $42000.0 in 2020, then decreased by 14.29% to $36000.0 in 2021, then jumped by 213.89% to $113000.0 in 2022, then soared by 34.51% to $152000.0 in 2023.
- Business Quant data shows LCTX's Invested Capital at $152000.0 in Q3 2023, $167000.0 in Q2 2023, and $184000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 190.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 380.00 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 152,000.00 |
| Jun 30, 2023 | 167,000.00 |
| Mar 31, 2023 | 184,000.00 |
| Dec 31, 2022 | 113,000.00 |
| Sep 30, 2022 | 41,000.00 |
| Jun 30, 2022 | 48,000.00 |
| Mar 31, 2022 | 57,000.00 |
| Dec 31, 2021 | 36,000.00 |
| Sep 30, 2021 | 29,000.00 |
| Jun 30, 2021 | 33,000.00 |
| Mar 31, 2021 | 42,000.00 |
| Dec 31, 2020 | 42,000.00 |
| Sep 30, 2020 | 44,000.00 |
| Jun 30, 2020 | 93,000.00 |
| Mar 31, 2020 | 102,000.00 |
| Dec 31, 2019 | 110,000.00 |
| Sep 30, 2019 | 120,000.00 |
| Jun 30, 2019 | 126,000.00 |
| Dec 31, 2015 | 33,800.00 |
| Jun 30, 2015 | 3,000.00 |